A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination
Advanced KRAS Positive Metastatic Colorectal Cancer
DRUG: MEK162 and mFOLFIRI
Incidence of dose limiting toxicities (DLTs) of combination MEK162 and mFOLFIRI, Patient safety will be evaluated throughout the treatment period (treatment with MEK162 and mFOLFIRI which is expected to last 6-10 months for each patient)
Response Rate, Changes in size of target lesions according to RECIST 1.1 to assess PR/CR, 2 months|Clinical benefit rate, Changes in size of target lesions according to RECIST 1.1 to assess PR/CR/SD at 4 months, 4 months|Additional Safety, Incidence of adverse events, 9 months|Progression-free survival, 9 months
This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination